- Home
- ACRE vs DCTH Comparison
ACRE vs DCTH Comparison
Compare ACRE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- DCTH
- Stock Information
- Founded
- ACRE 2011
- DCTH 1988
- Country
- ACRE United States
- DCTH United States
- Employees
- ACRE N/A
- DCTH N/A
- Industry
- ACRE Real Estate Investment Trusts
- DCTH Medical/Dental Instruments
- Sector
- ACRE Real Estate
- DCTH Health Care
- Exchange
- ACRE Nasdaq
- DCTH Nasdaq
- Market Cap
- ACRE 351.6M
- DCTH 305.2M
- IPO Year
- ACRE 2012
- DCTH N/A
- Fundamental
- Price
- ACRE $7.30
- DCTH $11.20
- Analyst Decision
- ACRE Hold
- DCTH Strong Buy
- Analyst Count
- ACRE 7
- DCTH 4
- Target Price
- ACRE $7.10
- DCTH $21.50
- AVG Volume (30 Days)
- ACRE 442.9K
- DCTH 363.4K
- Earning Date
- ACRE 11-07-2024
- DCTH 11-08-2024
- Dividend Yield
- ACRE 13.86%
- DCTH N/A
- EPS Growth
- ACRE N/A
- DCTH N/A
- EPS
- ACRE N/A
- DCTH N/A
- Revenue
- ACRE $39,423,000.00
- DCTH $11,878,000.00
- Revenue This Year
- ACRE N/A
- DCTH $1,562.76
- Revenue Next Year
- ACRE $0.48
- DCTH $117.72
- P/E Ratio
- ACRE N/A
- DCTH N/A
- Revenue Growth
- ACRE N/A
- DCTH 350.44
- 52 Week Low
- ACRE $6.25
- DCTH $2.25
- 52 Week High
- ACRE $11.24
- DCTH $11.75
- Technical
- Relative Strength Index (RSI)
- ACRE 66.58
- DCTH 73.49
- Support Level
- ACRE $6.25
- DCTH $10.11
- Resistance Level
- ACRE $6.53
- DCTH $11.24
- Average True Range (ATR)
- ACRE 0.20
- DCTH 0.57
- MACD
- ACRE 0.06
- DCTH 0.08
- Stochastic Oscillator
- ACRE 85.71
- DCTH 79.24
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.